CJC 1295 IPA (No DAC)

CJC 1295 IPA (no DAC) is a modified form of the long-acting peptide CJC-1295, designed for use in controlled laboratory settings. This compound is widely studied in preclinical research for its potential effects on growth hormone (GH) secretion, cell proliferation, and tissue regeneration. The “IPA” in its designation refers to its inclusion in an intermediate formulation that does not require des-arginine-amide conjugation (DAC), allowing for extended half-life and sustained hormone activity. Due to its research applications, it is exclusively intended for use within authorized academic, pharmaceutical, or biotech institutions.

Research Context

CJC 1295 is a non-peptide growth hormone secretagogue originally developed as a synthetic analogue to enhance human growth hormone (HGH) release. In preclinical models, CJC 1295 has been evaluated for its potential to improve tissue regeneration, reduce inflammation, and support metabolic processes. The “no DAC” variant is engineered to avoid the terminal arginine-amide modification, which may alter pharmacokinetics or binding affinity compared to traditional DAC formulations. Research has primarily focused on its role in enhancing GH signaling in rodents and other small animal models, though human data remain limited to controlled clinical studies.

Research Overview

CJC 1295 IPA (no DAC) is characterized by its ability to sustain GH secretion over extended periods, often extending beyond 24 hours in rodent studies. Its mechanism of action primarily involves activation of the pituitary GH-releasing hormone (GHRH) receptor, leading to downstream effects on somatotropin release. The absence of DAC modification may influence its half-life and clearance rate compared to standard CJC-1295, influencing its efficacy and safety profile in research settings. This compound is critical in preclinical studies examining aging, muscle atrophy, and metabolic syndrome, where GH dysregulation is implicated.

Key Research Focus Areas

• Growth Hormone Secretion: Evaluation of sustained GH release in comparison to standard CJC-1295 DAC formulations.
• Muscle and Tissue Regeneration: Investigation of its effects on muscle hypertrophy, wound healing, and extracellular matrix remodeling in rodent models.
• Anti-Aging Mechanisms: Analysis of potential anti-aging effects, including improvements in collagen synthesis and cellular repair pathways.
• Metabolic Function: Assessment of glucose and lipid metabolism modulation under controlled research conditions.
• Pharmacokinetic Studies: Comparison of clearance rates and systemic distribution between DAC and no-DAC variants.

Important Compliance and Safety Notice

This product is intended solely for research purposes in accredited academic, pharmaceutical, or biotechnology institutions. Unauthorized distribution, use, or possession is strictly prohibited under applicable laws. CJC 1295 IPA (no DAC) should only be handled and stored according to standard laboratory safety protocols. No therapeutic, diagnostic, or cosmetic claims are made, nor should this compound be used for human or animal consumption. Researchers are advised to consult their institution’s regulatory compliance officers and adhere to all applicable guidelines.

For research use only. Not for human or animal consumption.